Psilocybin for Mental Health and Addiction: What You Need To Know

A third meta-analysis found that half of psilocybin’s maximal antidepressant effect occurred with a dose of about 10 mg per 70 kg body weight, while 95% of the maximal effect occurred at a dose of about 41 mg per 70 kg body weight, and that higher doses might especially be better for treatment-resistant depression. Meta-analyses of psychedelics for depression and other psychiatric conditions have found that psilocybin has the greatest number of studies and the most evidence of benefit, relative to other psychedelics like ayahuasca and LSD. A June 2024 report by the RAND Corporation suggests the total number of use days for psychedelics is two orders of magnitude smaller than it is for cannabis, and unlike people who use cannabis and many other drugs, infrequent users of psychedelics account for most of the total days of use. In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public, psilocybin and other hallucinogenic drugs were unfavorably covered in the press and faced increasingly restrictive laws. Dozens of species of psychedelic mushrooms are found in Europe, but there is little documented usage of them in Old World history besides the use of Amanita muscaria among Siberian peoples. The diversity of psilocybin mushrooms is reported to have been increased by horizontal transfer of the psilocybin gene cluster between unrelated mushroom species.

Factors influencing legal status

Psilocybin, found in what is colloquially referred to as ‘magic mushrooms,’ is a hallucinogenic substance that is illegal in the United States under federal law. Psilocybin mushrooms were researched from the 1950s to the 1970s by a few prominent academics, including Harvard University’s Timothy Leary and Richard Alpert (later Ram Dass). There are more than 100 psilocybin mushroom species worldwide, the majority of which are members of the genus Psilocybe. Psilocybin mushroom, any of several species of hallucinogenic fungi found across a number of genera, especially Psilocybe mexicana and P. cubensis.

Side Effects

Some psychoactive species contain baeocystin, norbaeocystin and β‐carboline monoamine oxidase inhibitors in addition to psilocin and psilocybin. After psilocybin has been ingested and dephosphorylated, to psilocin, the mechanism it uses in the brain has a direct agonist effect on the 5-HT serotonin receptors. The blue-staining species of Psilocybe are characterized by the presence of psilocin and psilocybin. Most clinical trials of psilocybin for depression have had financial conflicts of interest and significant risk of bias. Another meta-analysis, which included only RCTs, found that 25 mg was the most effective dose, relative to lower doses like 10 mg and 0.215 mg/kg body weight (~15 mg for a 70-kg person).

About Medical News Today

Are a variety of Psilocybe mushrooms that make up the teonanácatl group of hallucinogenic mushrooms, including P. cubensis. They found that the psychoactive chemicals psilocybin and psilocin exhibited serotonin-like effects, however as dosage increased, these compounds acted as serotonin antagonists, psilocybin being comparable to the most potent antagonist yet discovered. Questions remain concerning the durability of psilocybin’s antidepressant effects, the scalability of its treatment delivery, and regulatory uncertainty.

• A 2002 study of the molecular phylogeny of the agarics indicated the genus Psilocybe as then defined was polyphyletic, falling into two distinct clades that are not directly related to each other.
• In particular, Shirota et al. reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4-hydroxyindole that does not require chromatographic purification.
• The lethal dose from psilocybin toxicity alone is unknown, and has rarely been documented—as of 2011update, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature, and those may involve factors other than psilocybin.d
• Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
• The elimination half-life of psilocybin, as psilocin, is 2.1 to 4.7 hours on average (range 1.2–18.6 hours) orally and 1.2 hours (range 1.8–4.5 hours) intravenously.
• These effects have a potency similar to that of (R)-DOI, and its anti-inflammatory effects occur at far lower doses than those that produce hallucinogen-like effects in animals.

Notable species

Often considered sacred, the mushrooms have been important for healing, divination, and spiritual rites in a number of cultures. Psilocybin mushrooms have been used for hundreds or thousands of years by Indigenous groups around the world. A growing body of research has suggested that psilocybin combined with psychotherapy may be helpful for depression in the short and medium term. Because of limitations in the design of the studies and the small number and health status of the people involved, the authors note that the conclusions may have been biased.

• Leary and colleagues proposed that psilocybin heightens suggestibility, making a user more receptive to interpersonal interactions and environmental stimuli.
• Single-dose psilocybin for a treatment-resistant episode of major depression.
• Activation of one serotonin receptor, the serotonin 5-HT2A receptor, is specifically responsible for the hallucinogenic effects of psilocin and other serotonergic psychedelics.
• According to the National Institute on Drug Abuse, people can continue to experience flashbacks anywhere from weeks to years after using the hallucinogen.
• In 1956, Roger Heim identified the hallucinogenic mushroom that the Wassons had brought back from Mexico as Psilocybe and in 1958, Albert Hofmann first reported psilocin and psilocybin as the active compound in these mushrooms.

Can someone stop a mushroom trip after ingestion?

In 1958, the Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the mushroom Psilocybe mexicana. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Risks of psilocybin

Psilocybin produces profound anti-inflammatory effects mediated by serotonin 5-HT2A receptor activation in preclinical studies. Serotonin 5-HT2C receptor activation and downstream inhibition of the mesolimbic dopamine pathway may be involved in the limited addictive potential of serotonergic psychedelics like psilocybin. In humans, ketanserin blocked psilocybin’s hallucinogenic effects but not all of its cognitive and behavioral effects. In addition, the serotonin 5-HT1B receptor has been found to be required for psilocybin’s persisting antidepressant- and anxiolytic-like effects as well as acute hypolocomotion in animals. Psilocybin’s psychedelic effects can be blocked by serotonin 5-HT2A receptor antagonists like ketanserin and risperidone in humans. Psilocybin is a serotonergic psychedelic that acts as a prodrug of psilocin, the active form of the drug.

Although the determination of psilocin levels in urine can be performed without sample cleanup (i.e., removing potential contaminants that make it difficult to accurately assess concentration), the analysis in plasma or serum requires preliminary extraction followed by derivatization of the extracts in the case of GC–MS. Ehrlich’s reagent and DMACA reagent are used as chemical sprays to detect the drug after thin layer chromatography. The drug produces a yellow color in the Marquis test and a green color in the Mandelin reagent. In particular, Shirota et al. reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4-hydroxyindole that does not require chromatographic purification.

Psilocin is the chemical primarily responsible for the hallucinogenic effects of the Psilocybe. After ingestion of the psilocybin compound alkaline phosphatases present in the body’s digestive system, kidneys, and possibly in the blood readily cleave the phosphoryl ester bond from psilocybin, yielding the hydroxyl compound, psilocin. Hydroxylation of this compound produces the more potent hallucinogen psilocin, followed by phosphorylation yielding psilocybin. The psilocybin molecule is indirectly responsible for the hallucinogenic properties of the Psilocybe.

In addition to interacting with the serotonin receptors, psilocin is a partial serotonin releasing agent with lower potency. Psilocin’s affinity for the serotonin 5-HT2A receptor is 15-fold higher in humans than in rats due to species differences. Psilocin is a close analogue of the monoamine neurotransmitter serotonin and, like serotonin, acts as a non-selective agonist of the serotonin receptors, including behaving as a partial agonist of the serotonin 5-HT2A receptor. Diclofenac and probenecid are inhibitors of these enzymes that theoretically might inhibit the metabolism of and thereby potentiate psilocybin’s effects, but no clinical research or evidence on this possible interaction exists.

Psilocybin – Uses, Side Effects, and More

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Effects of psilocybin therapy on personality structure.

This effect explains the euphoria experienced by ingestion of this “agonist.” Initially, hallucinogens were thought to blockade these serotonin neurotransmitters, but persistent research led to this agonist effect conclusion. To explain this effect, the psilocin molecule essentially mimics the serotonin molecule, binding to the 5-HT receptors and initiating the same response as the serotonin. The chemical structure of serotonin, a neurotransmitter, is similar to that of psilocin. Psilocybin is chemically far more stable than psilocin, the latter compound being largely lost when the mushroom is heated or dried. The degree of bluing in a Psilocybe fruit body roughly correlates with the concentration of psilocin in the mushroom.

What impacts effects?

The NCCIH Clearinghouse provides information on NCCIH and complementary and integrative health approaches, including publications and searches of Federal databases of scientific and medical literature. A small amount of research has looked at the use of psilocybin for anxiety and existential distress in serious medical illnesses like advanced cancer. Participants who received the psilocybin-assisted psychotherapy had fewer heavy drinking days over 32 weeks, which suggests that psilocybin may be helpful for alcohol use disorder. Other states have proposed or enacted psilocybin-specific legislation to regulate its production, sale, or supervised administration. Despite its status as a Schedule 1 controlled substance at the Federal level, possession of psilocybin has been either decriminalized or deprioritized in some states psilocybe semilanceata habitat and the District of Columbia.

In many countries, including Russia, India, and South Africa, psilocybin is illegal. The substance itself is classified as a Schedule I controlled substance, while the mushrooms as a whole are not. Currently, where psilocybin-assisted therapy is legal, it is only permitted to be used in approved treatment centers and administered by licensed professionals. This has led to the increased use of psilocybin-assisted therapy in approved treatment centers.

In 2025, numerous state-level psilocybin law reforms were introduced during legislative sessions, but only a few were ultimately passed. As discussed in the above table, legislation around the legality of personal and medicinal psilocybin use is ever-changing. It is legal for medicinal use in countries including Canada, Australia, and Denmark.